Oncological outcomes and prognostic factors after nephron-sparing surgery in renal cell carcinoma

PURPOSE - To analyse the mid-term oncological results and to asses predictive factors for recurrence and survival after nephron-sparing surgery (NSS) for renal cell carcinoma.

MATERIALS AND METHODS - This is a retrospective study that includes 198 Partial Nephrectomies performed at our institution for malignant renal tumours.

Demographic information and pathological characteristics were obtained, and completed statistical analysis was performed to assess predictors for overall survival (OS) and overall recurrence in our sample.

RESULTS - The presence of positive surgical margins (PSM) in the surgical specimen was reported in 13. 6 %. At a median of follow-up of 56. 1 months, the non-adjusted cancer-specific mortality, DSS and OS were 100, and 93. 4 %, respectively. In the bivariate analysis regarding predictive factors for recurrence, bilaterality and NSS indication (elective or imperative) were statistically significant (p = 0. 03 and p = 0. 05 respectively). On multivariate analysis only bilaterality was a significant predictor of recurrence (p = 0. 03), while high Fuhrman grade was for survival (p = 0. 006).

CONCLUSIONS - Our data suggest that patients with bilateral tumours have a higher incidence of local recurrence. Regarding overall survival, our data showed more risk of death at 5 years in those patients with high Fuhrman grade. No differences were found among PSM and negative surgical margins patients regarding oncological outcomes.

International urology and nephrology. 2016 Feb 09 [Epub ahead of print]

Miguel Ángel López-Costea, Xavier Bonet, Jose Pérez-Reggeti, Begoña Etcheverry, Francisco Vigués

Department of Urology, Hospital Universitari de Bellvitge, University of Barcelona, 08907, Hospitalet de Llobregat, Barcelona, Spain. Department of Urology, Hospital Universitari de Bellvitge, University of Barcelona, 08907, Hospitalet de Llobregat, Barcelona, Spain. , Department of Urology, Hospital Universitari de Bellvitge, University of Barcelona, 08907, Hospitalet de Llobregat, Barcelona, Spain. , Department of Urology, Hospital Universitari de Bellvitge, University of Barcelona, 08907, Hospitalet de Llobregat, Barcelona, Spain. , Department of Urology, Hospital Universitari de Bellvitge, University of Barcelona, 08907, Hospitalet de Llobregat, Barcelona, Spain.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe